CCT-102 or Expectant Management in Delayed Pregnancy Loss

NCT06121063 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2025-08-22

No results posted yet for this study

Summary

A Phase 3, multi-center clinical trial of a CCT-102 regimen or expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL).

Conditions

  • Early Pregnancy Loss, Delayed Pregnancy Loss

Interventions

COMBINATION_PRODUCT

CCT-102 A and CCT-102 B

2 day oral regimen

Sponsors & Collaborators

  • Conceptra Biosciences, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-21
Primary Completion
2025-05-15
Completion
2025-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06121063 on ClinicalTrials.gov